Trial Profile

A real-world study to determine effectiveness of berotralstat treatment in patients who initiated berotralstat and were previously on another prophylactic therapy in US

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2024 Results published in the BioCryst Pharmac Media Release.
14 Oct 2024 According to a BioCryst Pharmac this euticals media release, study will be presented in a poster at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024 national meeting, which is being held in Las Vegas from October 14-17, 2024.
26 Feb 2024 Results evaluating rapid and sustained reductions in monthly attack rates in HAE patients regardless of C1-inhibitor function, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com